Sen. Brownback Wants FDA To Aggressively Coordinate Drug Development For Neglected/Rare Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
The Kansas Republican suggests the agency could get all parties, including investors, into the action to push therapies past the approval goal posts.
You may also be interested in...
FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
FDA will search for a new chief of its office just as interest in the rare disease space is increasing, particularly among large pharmaceutical companies.
FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
FDA will search for a new chief of its office just as interest in the rare disease space is increasing, particularly among large pharmaceutical companies.
Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.